Background: To determine the "real world" relapse rate in patients with first-episode psychosis
| INTRODUCTION
Preventing relapse is one of the most important clinical targets in the management of first-episode psychosis (FEP); approximately 80% of patients treated following FEP, relapse within the first 5 years (Robinson et al., 1999; Wiersma, Nienhius, Slooff, & Giel, 1998) .
Relapse compromises the outcome of psychotic disorders, with each new episode significantly increasing the development of treatmentresistant symptoms.
It has been well established that maintenance medication plays an important role in reducing the risk of relapse amongst FEP patients (Kane, Rifkin, Quitkin, Nayak, & Ramos-Lorenzi, 1982) . However, the optimum duration of maintenance medication is yet to be determined and published guidelines are not united in their recommendations. A recent systematic review of 14 guidelines for maintenance treatment after a first-episode of schizophrenia found that six were not opposed to discontinuing antipsychotics after 1 to 2 years, whilst two discouraged discontinuation (Takeuchi, Suzuki, Uchida, Watanabe, & Mimura, 2012) . In the remaining six guidelines, medication discontinuation was not mentioned (Takeuchi et al., 2012) .
The question of how long to continue antipsychotic treatment after FEP is common amongst patients, and clinicians face difficulties 2 | METHODS
| Study setting and population
The study population was drawn from patients under the care of the Birmingham Early Intervention Service (EIS) between 2012 and 2015.
The EIS is responsible for the treatment of young people aged [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] with FEP. With a total caseload of approximately 700 patients, the service comprises five teams spanning the Birmingham and Solihull Mental Health Trust (BSMHFT); an area of diverse ethnic and sociodemographic communities.
Patients were included on meeting the following criteria:
• discontinued antipsychotic medication for any reason,
• had a clinical diagnosis of FEP conforming to ICD-10 codes F20-29, F30.2, F31.2, F31.5, F32.3 and F33.3 (World Health Organisation, 1992 ) (due to the diagnostic uncertainty during the early stages of psychosis, a broad diagnostic range was chosen),
• experienced a significant reduction of symptoms as judged by the clinical team prior to discontinuing medication (ie, had recovered).
Patients were excluded if they had (1) discontinued antipsychotic medication for less than 4 weeks, or (2) less than 4 weeks antipsychotic treatment prior to discontinuation (as these time periods were considered too short to be defined as discontinuation or as an effective treatment episode). Patients with insufficient case notes were also excluded.
| Study design
Quantitative data were obtained from retrospective electronic casenote review. Case records were analysed from the point medication was discontinued. The follow-up period was until: an occurrence of a relapse; the end of the 12-month study period; or the end of the patient's case record if less than 12 month's follow-up data (as this could be accounted for by statistical analysis). All data were extracted by the author and were based on routine assessment by clinicians as documented in BSMHFT electronic patient records.
| Procedure
The study protocol was disseminated to all clinical teams within the Birmingham EIS. Clinical teams identified patients who had discontinued medication between 2012 and 2015. Case notes of eligible patients were subsequently screened by the author using the eligibility criteria to determine the final sample.
| Ethical approval
The study protocol was approved by BSMHFT Research and Innovation department and by the BMedSc Population Sciences and Humanities Internal Ethics Review Committee. In accordance with National Research Ethics Service guidelines for a study involving previously collected routine clinical data, specific consent procedures were not required (NHS, 2013) and thus, the sample consisted of all patients who met the eligibility criteria. This definition is representative of the BSMHFT EIS procedure to detect a relapse of symptoms. Relapse evaluated was the first relapse following the patient's FEP. The relapse status, definition and time to relapse were recorded.
| Predictor variables
A standard pro-forma targeted pre-defined socio-demographic and clinical factors, and was developed from a systematic review that explored factors associated with relapse in FEP (Alvarez-Jimenez, Hetrick, et al., 2012) . Socio-demographic variables were evaluated upon study entry and included: age, gender, ethnicity, marital status, education level, accommodation, employment status and smoking status. Accommodation status was categorized into settled vs not settled; not settled was defined as being in supported housing or temporary accommodation. 
weeks). DUI was defined as the interval (in days)
between the onset of non-specific symptoms and the onset of criterion treatment. Both DUP and DUI data were based on routine standardized clinical interviews as recorded in case notes.
| Statistical analysis
A survival analysis was used to estimate the cumulative rate of relapse, with censoring of data to account for differentiated duration of follow-up of study subjects. Data were censored if no relapse occurred during follow-up.
Cox proportional hazards regression was used to identify predictors of relapse by examining time to relapse and its relationship with independent variables. Proportional hazard assumption was assessed graphically using log minus log survival plots. Univariate Cox proportional hazards regression analysis was first performed on each potential predictor. Variables with P ≤ .1 were entered into a multivariate Cox proportional hazards model. A forward stepwise likelihood ratio for variable selection was used in the multivariate model, with P < .05 as the entering criterion. Missing values were excluded from the analysis. A similar analysis was conducted in patients who did not relapse despite stopping medication to identify factors associated with non-relapse.
| RESULTS
A total of 133 patients were identified by the clinical teams' to have discontinued antipsychotics. Following assessment of eligibility, 70 (52.6%) were excluded from the study because of the following reasons: insufficient case notes (n = 29, 41.4%); not meeting inclusion criteria (n = 21, 30%) and discontinuation period of less than 4 weeks (n = 20). For those excluded for not meeting the inclusion criteria (n = 21, 30%), 18 were due to partial non-concordance (ie, not fully discontinued medication) and the remaining three due to a reduction in symptoms being deemed insignificant (as judged by the clinical team). Thus, data were collected for 63 patients. Table 1 summarizes the socio-demographic and clinical characteristics of the sample.
| Sample characteristics
The sample was 73% male and the median age at discontinuation was 22 years (inter-quartile range (IQR) = 6). The largest ethnic group was Asian (n = 22, 35.0%), followed by White (n = 17, 27.0%) and Black (n = 13, 20.6%). Two-thirds of the sample were classified as not being in education, employment or training (NEET) (n = 42, 66.7%).
The most common diagnosis categories were psychosis not otherwise specified (NOS) (n = 24, 38.1%) and schizophrenia (n = 21, 33.3%).
Prior to discontinuation, the median duration of antipsychotic treatment was 8.5 months (IQR = 11.3; range 1-36), of which oral medication was the most common type (n = 53, 84.1%). The median duration of follow-up was 6 months (IQR = 6 months).
| Relapse
Out of the 63 patients, 36 relapsed (57%) by the end of the 12 months; of those that relapsed, the majority resulted in either an informal or compulsory hospital admission (n = 19, 52.8%), with a greater proportion of compulsory admissions (n = 11, 30.6%). Taking into account censoring, the Kaplan-Meier estimate of the proportion relapsed at, or earlier than 12 months was 67% (95% confidence interval (CI), 54%, 80%) (Figure 1 ). The median time to relapse was 8 months (95% CI, 6.03, 9.97).
Given the differentiated length of antipsychotic treatment prior to discontinuation, patients were grouped into: ≤12 months antipsychotic treatment (n = 42, 66.7%) and >12 months treatment (n = 20, 31.7%). No significant differences were found in time to relapse in these two groups (X 2 = 0.001, d.f. = 1, P = .978).
| Predictors of relapse
Several of the socio-demographic and clinical variables explored were found to be statistically insignificant (P > .05) in the univariate analysis, and were: age at discontinuation, marital status, education level, accommodation, diagnosis, age at onset of FEP, DUP, DUI, psychiatric co-morbidities, psychiatric family history, duration of antipsychotic treatment and type of antipsychotic medication.
Results of the relapse predictors in the univariate Cox model analysis with P ≤ .1 are shown in Table 2 . Significant univariate predictors included male gender, NEET, number of previous psychiatric hospital admissions and substance misuse. Three independent predictors for relapse were identified from the multivariate Cox model analysis (Table 2) . Patients who were male had a 3.7 times higher risk of relapse (Exp B = 3.72; 95% CI, 1.42, 9.78; P = .008). NEET status was associated with a twofold increase in relapse risk when compared to being in education, training or employment (Exp B = 2.24; 95% CI, 1.01, 4.97; P = .047). The number of previous psychiatric hospital admissions was identified as a highly significant clinical predictor, with the risk of relapse increasing by approximately two times with every one unit increase in previous hospital admission (Exp B = 1.94; 95% CI, 1.31, 2.88; P = .001).
None of the identified risk factors were found to be statistically significant in predicting non-relapse in this sample of patients with first episode psychosis who had stopped their medication. Abbreviations: FEP, first-episode psychosis; DUI, duration of untreated illness; DUP, duration of untreated psychosis; IQR, inter-quartile range; n, number; NOS, not otherwise specified.
1 Two data missing.
2 Seven data missing.
3 Continuous variable.
4 Categorical variable.
5 One data missing.
FIGURE 1 Kaplan-Meier survival analysis for time to relapse following discontinuation of antipsychotic medication. + censored. n = 63. Cumulative relapse rate = 67%. Median time to relapse = 8 months.
| DISCUSSION
This study sought to address the "real world" relapse rate and to identify which factors (socio-demographic and clinical) were associated with relapse in a sample of FEP patients, who had discontinued antipsychotic medication. Approximately two-thirds of the sample relapsed within 12 months following discontinuation of antipsychotics, with male gender, NEET and increasing number of previous psychiatric hospitalizations being independently associated with a higher risk of relapse.
| Relapse
This study's relapse rate of 67% is in keeping with the literature, reporting between 41% and 80% of FEP patients who discontinue medication go on to relapse within the first year (Chen et al., 2010; Gitlin et al., 2001; Kane et al., 1982; Zipursky et al., 2014) . The higher relapse rates reported (approximately 80% (Gitlin et al., 2001; Chen et al., 2010; Zipursky et al., 2014) ). Nevertheless, it was based on the normal stepwise procedure used by the EIS to detect a relapse, therefore likely to be better representative of "real world" clinical practice. Additionally, previous research conducted by Chen et al. (2010) estimated a more pragmatic relapse rate (69%) based on information from case notes, including only relapses deemed clinically significant, which is comparable to the relapse estimated in this study.
The high hospitalization rate amongst those who relapsed demonstrated that this study captured clinically significant relapses.
This highlights the need for closer follow-up of patients once they are known to discontinue medication in order to identify relapses earlier before pronounced deterioration occurs. It would be useful for future studies to not only quantify relapse rates but also evaluate the clinical impact of the relapses.
An important finding was that relapse was not found to be related to the duration of previous antipsychotic medication (which ranged from 1 month to 36 months; median treatment duration being 8.5 months). This is concurrent with research by Chen et al. (2010) . Furthermore, from previous discontinuation trials, there is no apparent indication of reduced relapse risk with longer treatment periods. Discontinuation after 3, 12 and 24 months in three separate trials all reported 12-month relapse rates of around 80% (Chen et al., 2010; Emsley, Oosthuizen, Koen, Niehaus, & Martinez, 2012; Gitlin et al., 2001 ). This has implications for clinical practice, and suggests that lengthening treatment after a FEP does not reduce the relapse risk. However, the optimum point in time at which medication can safely be discontinued has yet to be established. Abbreviations: CI, confidence interval; Exp B, hazard ratio; NA, not applicable; NEET, not in employment, education or training.
1 Predictors with P-value ≤.1 in univariate analyses were entered in multivariate analysis.
2 Significant at 5% level.
3 Exp B (hazard ratio) represents relative increase in hazard with one unit increment in variable.
| Predictors of relapse
The strongest predictor was male gender, which was associated with approximately a fourfold increase in risk of relapse. Previous studies have been mixed with regards to the relationship between gender and relapse, with some suggesting an association (Angermeyer et al., 1989; Tohen et al., 1992) whilst others have failed to show any association (Johnstone et al., 1986; Kane et al., 1982) . Nonetheless, generally in FEP patients, gender effects have been reported with regards to functional outcome; male patients have been shown to have poorer functional outcome after a first-episode, suggesting males may have an increased vulnerability to relapse (Angermeyer et al., 1989) . Noteworthy, male gender has been reported to be a predictor of medication discontinuation (Kampman et al., 2002) and so the high proportion of males in this sample may have enhanced the apparent difference in relapse risk. Nevertheless, this higher proportion of males to females is compatible with the gender split seen in this EIS (Kam, Singh, & Upthegrove, 2015) .
NEET was associated with an approximately two times increased risk in relapse compared with those in employment, education or training. This finding ties in with a FEP follow-up study reporting early vocational recovery to be associated with longer-term recovery . Early vocational recovery is considered as a key component of recovery and it has been observed that those who only have one episode and recover fully are less likely to be NEET . NEET could be used as a broad measure of poor functional outcome and suggests the importance of interventions facilitating vocational recovery.
The association between previous number of psychiatric hospital admissions and increased relapse risk is concurrent with studies examining predictors of hospital readmission in schizophrenia (Mortensen & Eaton, 1994; Swett, 1995) . It has been shown that a history of hospitalization is associated with a higher chance of earlier rehospitalization in patients with schizophrenia (Olfson et al., 1999) .
Although in this study, previous psychiatric admissions related to admissions prior to the patients' FEP diagnosis, hospitalization typically indicates a higher level of symptom severity experienced by patients. Therefore, it could suggest patients with previous psychiatric admissions (prior to FEP) go onto have a more unstable illness.
| Strengths and limitations
The diverse ethnic sample, the inclusion of all-cause discontinuation and patients not limited to those with motivation and capacity to consent allowed an estimate of relapse, which is perhaps more generalizable to typical clinical practice.
However, these findings must be interpreted in light of a number of limitations.
The method used to determine the sample likely introduced recall and selection biases. The method involved clinicians identifying patients who had discontinued medication; clinicians are more likely to recall those patients who had previously discontinued medication, which resulted in a relapse, likely inflating the relapse estimate. Furthermore, patients who discontinued medication covertly and those who had successfully discontinued may have been less likely to have been identified. These biases perhaps could have been reduced through screening a random selection of patients, stratified by demographic and clinical factors, within the EIS using the eligibility criteria.
Plasma antipsychotic levels monitoring would be the ideal way to establish adherence to medication, which was not available in this study due to the design constraints.
The reliability of the relapse and predictor estimates was further limited by the small sample size. The sample size may have been insufficient to detect weaker predictors and was also restricted by the quality of the case notes: a high proportion of the potentially eligible sample was excluded due to insufficient case notes (41%) and it is possible that a proportion of these might have successfully fulfilled the eligibility criteria.
It is important to note that for inclusion, patients were judged as having significant reduction in symptoms before discontinuation; however, the time period for the recovery was not specified, which could have been a factor associated with relapse. Other potentially important relapse factors were not captured, such as level of insight and past adherence. Larger sample sizes and prospective longitudinal studies are required to be able account for these limitations.
| CONCLUSION
Relapse is common in "real world" clinical practice following discontinuation of antipsychotic medication following recovery from a FEP.
It is important for clinicians to inform patients who wish to discontinue their medication of the high relapse rates, and should ensure closer monitoring of patients who discontinue medication. Patients who are male, NEET status and have a history of psychiatric admissions should be recognized by health-care professionals as having an increased risk of relapse, and suggests continued medication in these patients. However, these findings need to be replicated in larger independent samples. It may also be useful for future work to identify those patients who can discontinue medication without risk of relapse through investigating factors that may be protective. This will further aid clinicians' decision-making when confronted with patients requesting discontinuation.
